10-Q: Pressure BioSciences Reports Q2 2024 Results, Cites Revenue Decline and Ongoing Financial Challenges

Pressure BioSciences, Inc. reports a decrease in revenue for Q2 2024 and the first half of the year, alongside ongoing concerns about its ability to continue as a going concern.

Summary

• Pressure BioSciences, Inc. (PBIO) reported its financial results for the second quarter of 2024.
• The company experienced a decrease in revenue, with Q2 2024 revenue at $421,792 compared to $511,803 in Q2 2023, representing an 18% decrease.
• Year-to-date revenue also decreased by 38%, from $1,252,403 in 2023 to $771,049 in 2024.
• The decrease in revenue is attributed to lower sales of cell disruptor instruments, PBI Agrochem materials, and PCT instruments and consumables.
• The company's cost of products and services was $377,541 for Q2 2024, compared to $256,599 for Q2 2023.
• Gross profit margin decreased to 21% for the first six months of 2024, down from 51% in the same period of 2023.
• Research and development expenses were $296,146 for Q2 2024, compared to $280,446 for Q2 2023.
• Selling and marketing expenses were $156,892 for Q2 2024, compared to $154,014 for Q2 2023.
• General and administrative expenses were $1,519,753 for Q2 2024, compared to $902,265 for Q2 2023.
• The operating loss was $1,928,540 for Q2 2024, compared to $1,081,521 for Q2 2023.
• Net loss attributable to common stockholders was $7,748,534 ($0.15 per share) for Q2 2024, compared to $11,114,925 ($0.57 per share) for Q2 2023.
• The company acknowledges substantial doubt about its ability to continue as a going concern due to negative cash flows and inadequate working capital.
• PBIO is pursuing debt and equity financing to address its liquidity concerns.
• From July 1, 2024, through February 7, 2025, the Company issued four (4) convertible loans for approximately $ 1,912,199 , which each carry a 0 10 % annual interest rate and one (1) to twelve (12) month terms.
• From July 1, 2024, through February 7, 2025, 65,000 shares of common stock were issued for loan extensions, 10,462,872 shares issued for default and paid-in-kind and 1,219,403 shares of common stock for dividends paid-in-kind.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture, with declining revenue, increasing losses, and doubts about the company's ability to continue as a going concern. While there are some positive aspects, such as the acquisition of Uncle Buds, the overall sentiment is negative.

Positives

• The company completed the acquisition of Uncle Buds Health & Wellness in January 2024, adding a direct-to-consumer revenue stream.
• The company is actively pursuing debt and equity financing to address its liquidity concerns.
• The company has relocated into a new facility with increased manufacturing space and improved efficiencies.
• The company has a portfolio of patented high-pressure platforms, including Ultra Shear Technology (UST), BaroFold Technology, and Pressure Cycling Technology (PCT).

Negatives

• The company experienced a significant decrease in revenue for both Q2 2024 and the year-to-date period.
• The gross profit margin decreased substantially, indicating lower profitability on sales.
• The company reported a significant operating loss for Q2 2024.
• The company acknowledges substantial doubt about its ability to continue as a going concern.
• The company has a history of negative cash flows from operations.

Risks

• The company's ability to continue as a going concern is uncertain due to inadequate working capital and negative cash flows.
• The company's success depends on its ability to raise additional capital through debt and equity offerings.
• Failure to obtain financing on acceptable terms could force the company to cease operations or sell assets.
• The company faces risks related to the integration of Uncle Buds Health & Wellness and the success of its consumer products.
• Any interruption to the Uncle Buds website or marketing expenditures could negatively impact sales revenues.
• The company's reliance on a few key customers and federal agencies creates concentration risk.
• The company's debt includes convertible notes with variable conversion rates that could dilute existing shareholders.
• The company's internal controls over financial reporting are not effective, which could lead to errors in financial reporting.

Future Outlook

The company will need substantial additional capital to fund our operations in future periods. If we are unable to obtain financing on acceptable terms, or at all, we will likely be required to cease our operations, pursue a plan to sell our operating assets, or otherwise modify our business strategy, which could materially harm our future business prospects.

Industry Context

The company operates in the life sciences and consumer products industries, which are subject to intense competition and rapid technological change. The company's success depends on its ability to innovate and adapt to changing market conditions.

Comparison to Industry Standards

• It is difficult to compare PBIO's results directly to industry standards due to its unique combination of life science tools and consumer products.
• Companies like Thermo Fisher Scientific and Danaher Corporation are major players in the life science tools market, but they have significantly larger scale and resources.
• In the consumer products market, PBIO's Uncle Buds competes with numerous established brands in the health and wellness space.
• PBIO's financial performance lags behind industry leaders in both sectors, reflecting its smaller size and limited resources.

Related Party Transactions

• During the six months ended June 30, 2024, we received short-term convertible loans of $ 308,229 with $ 30,823 OID from related parties and repaid $ 104,700 of related party loans.
• These notes bear interest of 12 % to 120 % and are due upon demand.
• All related party notes are convertible at $ 2.50 /share.

Stakeholder Impact

• Shareholders face the risk of dilution due to potential equity offerings and convertible debt.
• Employees face uncertainty due to the company's financial challenges and potential need to cease operations.
• Customers may be concerned about the company's ability to continue providing products and services.
• Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company needs to secure additional financing to fund its operations.
• The company needs to improve its revenue and profitability.
• The company needs to address its material weaknesses in internal control over financial reporting.

Key Dates

Keywords

financial results, revenue, net loss, going concern, Pressure BioSciences, Uncle Buds, convertible debt, liquidity, financing, UST, PCT, BaroFold